393 материалов по теме, собраны автоматически из проверенных источников
Some people with advanced lung cancer have no approved targeted treatment. A drug combination is now being tested. Stock Titan
Lung cancer: new approach to reduce radiation-related damage healthcare-in-europe.com
Kristian Jensen Announces New Global Lung Cancer Medical Affairs Position at GSK Oncodaily
A lung cancer drug showed a 68% response rate at the higher dose. No targeted standard exists for this mutation. Stock Titan
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 Morningstar
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 PR Newswire
Сигарет не было, а рак лёгких появился: опасность может скрываться даже в воздухе собственного дома Правда.Ру
GSK lung cancer drug shows 61% response rate in early global trial Proactive financial news
GSK lung cancer drug shows 61% response rate in early global trial Yahoo Finance UK
Постоянный кашель, последовавший за осмотром у ЛОР-врача, выявил рак легких. Vietnam.vn
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer mykxlg.com
Cofactor Genomics Publishes OncoPrism-NSCLC Clinical Validation, Advancing Lung Cancer Immunotherapy Diagnostics Beyond PD-L1 BioSpace
Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice Nature
Charles Truillet Shares Research Opportunity in Lung Cancer Immunotherapy Resistance Oncodaily
Real-World Outcomes After Selective RET Inhibitor Failure in Metastatic Lung Cancer Oncodaily